Firebrick Pharma recruits first patient for its confirmatory Phase 3 trial of Nasodine Nasal Spray as a treatment for the common cold.
It’s been a busy period for Firebrick Pharma as the Australian pharmaceutical company has now recruited the first patient for its Phase 3 trial for its Nasodine Nasal Spray as a treatment for the common cold.
Firebrick Pharma Executive Chairman Dr Peter Molloy joined Grafa’s Grady Wulff to discuss the recent announcement.
Read the full story
in the Grafa app
To read the full article and more in the Grafa app, available on all app stores.
Track the trends
Get the hot tips first
Stay close to your investments
Learn to trade like a pro
Let your money entertain you